The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza Combination ...
(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...
The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza ...
Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible. Also Read: DeSantis Administration Cautions Against Pfizer, Moderna ...
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...
In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...
On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...
Novavax ( (NVAX) ) has issued an announcement. Novavax, Inc. and the UK Health Security Agency have reached a settlement to terminate their ...
Shares in Novavax fell by as much as one-fifth Wednesday morning after the company disclosed the Food and Drug Administration halted clinical testing of its combination vaccine for COVID-19 and ...